India developing bulk drugs to reduce import dependence

The country's import of active pharmaceutical ingredients (APIs) from China is high but there is enough capacity for domestic production, says DGCI
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news